Table 2 Sample’s characteristics, according to the presence of no DM or prediabetes, accessed by HbA1c
HbA1c | P value | ||
|---|---|---|---|
<5.7% | 5.7–6.4% | ||
n (%) | 189 (85.9) | 31 (14.1) | |
Sex [n (%)] | 0.623 | ||
Male | 116 (61.4) | 17 (54.8) | |
Female | 73 (38.6) | 14 (45.2) | |
Age [years, mean (SD)] | 45 (11.3) | 50.4 (11.9) | 0.016 |
Duration of HIV infection [years, median (IR)] | 8 (6) | 8 (7.0) | 0.698 |
cART [years, median (IR)] | 6 (6.5) | 7 (7.0) | 0.136 |
Clinical lipodystrophy [n (%)] | 0.909 | ||
Without CL | 91 (48.1) | 14 (45.2) | |
With CL | 98 (51.9) | 17 (54.8) | |
Body Composition [n (%)] | 0.469 | ||
No lipodystrophy | 28 (15.3) | 3 (10) | |
Isolated central fat accumulation | 59 (32.2) | 10 (33.3) | |
Lipoatrophy | 52 (28.4) | 6 (20) | |
Mixed form of lipodystrophy | 44 (24) | 11 (36.7) | |
BMI [(kg/m2), mean (SD)] | 25 (4.5) | 26.9 (4.5) | 0.031 |
Waist circumference [cm, mean (SD)] | 90.9 (11.6) | 95.2 (13.2) | 0.065 |
CD4 cell count [cells/mm3, median (IR)] | 500 (345) | 528 (312) | 0.819 |
HIV RNA (<50) [n (%)] | 165 (100) | 27 (100) | |
Hepatitis C co-infection [n (%)] | 57 (30.8) | 7 (22.6) | 0.474 |
CDC clinical categories [n (%)] | 0.093 | ||
A | 107 (56.6) | 12 (38.7) | |
B | 5 (2.6) | 0 (0) | |
C | 77 (40.7) | 19 (61.3) | |
ART [n (%)] | |||
IP | 106 (56.1) | 17 (54.8) | 0.999 |
NNRTI | 88 (46.6) | 14 (45.2) | 0.999 |
NRTI | 182 (96.3) | 28 (90.3) | 0.152 |
HOMA-IR index [median (IR)] | 1.6 (1.5) | 2.5 (5.1) | 0.023 |
QUICKI index [median (IR)] | 0.4 (0.1) | 0.3 (0.1) | 0.023 |
Total cholesterol [mg/dL, mean (SD)] | 225.6 (55.4) | 219 (55.8) | 0.544 |
LDL- cholesterol [mg/dL, mean (SD)] | 133.5 (47.5) | 140.2 (44.6) | 0.473 |
HDL- cholesterol [mg/dL, mean (SD)] | 48.3 (14.4) | 45.8 (11.8) | 0.374 |
Triglycerides [mg/dL, median (IR)] | 203 (198) | 139 (133.8) | 0.010 |
Statin use [n (%)] | 41 (21.7) | 5 (16.1) | 0.640 |
Fibrate use [n (%)] | 61 (32.3) | 4 (12.9) | 0.048 |